Showing 4231-4240 of 5771 results for "".
- NIH-Sponsored Trial Finds Eylea Reduced Vision-Threatening Complications by 68% After 2 Years in DR Patientshttps://modernod.com/news/nih-sponsored-trial-finds-eylea-reduced-vision-threatening-complications-by-68-after-2-years-in-diabetic-retinopathy-patients/2479034/Regeneron Pharmaceuticals announced that JAMA Ophthalmology has
- Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept Agreement for Two Ophthalmic Drug Candidateshttps://modernod.com/news/nanoform-and-nacuity-pharmaceuticals-sign-technology-proof-of-concept-agreement-for-two-ophthalmic-drug-candidates/2479035/Nanoform Finland and Nacuity Pharmaceuticals announced that they have signed a Technology Proof of Concept Agreement, with compensation on standard commercial terms. This will apply Nanoform’s nanoparticle CESS technology to enhance ophthalmic drug delivery of Nacuity’s NPI-001 and N
- AffaMed Therapeutics Completes $170 Million Series B Financing to Further Development of Ophthalmic and Neuroscience Pipelinehttps://modernod.com/news/affamed-therapeutics-completes-170-million-series-b-financing-to-further-development-of-ophthalmic-and-neuroscience-pipeline/2479029/AffaMed Therapeutics announced the completion of over $170 million in Series B financing. Proceeds from the financing will be used to advance clinical development of AffaMed’s pipeline of innovative therapeutic candidates, progress business development and partnering activities, and support
- Retina Consultants of America Adds Carolina Retina Centerhttps://modernod.com/news/retina-consultants-of-america-adds-carolina-retina-center/2479023/Retina Consultants of America (RCA), a physician management services organization, announced it has added Carolina Retina Center of Columbia, South Carolina to its group of retina practices. The addition of Carolina Retina Center is RCA’a 10th practice in South Carolina, and bo
- NeurOptics Launches Pupillometry Program at Vanderbilt University Medical Centerhttps://modernod.com/news/neuroptics-launches-pupillometry-program-at-vanderbilt-university-medical-center/2479015/NeurOptics recently announced that its NPi-200 pupillometers and the Neurological Pupil Index (NPi) are now being used in the Neurological Intensive Care Unit at Vanderbilt University Medical Center, in Nashville, Tennessee, as an important measurement for managing patients with brain injury.
- Visus Therapeutics Initiates Phase 2 Clinical Trial of Brimochol for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-initiates-phase-2-clinical-trial-of-brimochol-for-the-treatment-of-presbyopia/2479013/Visus Therapeutics announced the commencement of its phase 2 clinical trial of Brimochol topical ophthalmic solution under investigation for the treatment of presbyopia. Brimochol is a proprietary pupil-modulating eye drop that combines two well-studied, FDA-approved pharmaceuticals: carb
- Johnson & Johnson Vision Receives Approval in Japan for First Drug-Releasing Combination Contact Lens for Vision Correction and Allergic Eye Itchhttps://modernod.com/news/johnson-johnson-vision-receives-approval-in-japan-for-first-drug-releasing-combination-contact-lens-for-vision-correction-and-allergic-eye-itch/2479010/Johnson & Johnson Vision announced approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the first and only vision correction contact lens that relieves allergic eye itch: Acuvue Theravision with Ketotifen. The lens contains ketotifen, an H1 histamine receptor antagonis
- Lineage Cell Therapeutics Presents Additional Interim Data on OpRegen for Dry AMD With Geographic Atrophyhttps://modernod.com/news/lineage-cell-therapeutics-presents-additional-interim-data-on-opregen-for-dry-amd-with-geographic-atrophy/2479007/Lineage Cell Therapeutics announced new positive interim results from its ongoing, 24-patient phase 1/2a clinical study of its lead product candidate, OpRegen. OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal
- Aura Biosciences Names Mark De Rosch, PhD, Chief Operating Officerhttps://modernod.com/news/aura-biosciences-names-mark-de-rosch-phd-chief-operating-officer/2479008/Aura Biosciences announced the appointment of Mark De Rosch, PhD, as Chief Operating Officer. In his role, he will be responsible for leading Aura’s global operations and regulatory strategy. Dr. De Rosch brings to Aura more than 30 years of experience in leading global regulatory and deve
- Uplinza Approved in Japan for the Prevention of Relapses of Neuromyelitis Optica Spectrum Disorder (NMOSD)https://modernod.com/news/uplinza-approved-in-japan-for-the-prevention-of-relapses-of-neuromyelitis-optica-spectrum-disorder-nmosd/2479009/Horizon Therapeutics announced that its strategic partner Mitsubishi Tanabe Pharma Corporation (MTPC) has received manufacturing and marketing approval of Uplinza for the prevention of relapses of neuromyelitis optica spectrum disorder (including neuromyelitis optica) from the Japanese Ministry o